(a).
| Drug | Intervention | Primary endpoint\ | N | Follow-up time (years) |
Mean age | Mean HbA1c levels (%) | Previous cardiovascular status of patients | |
|---|---|---|---|---|---|---|---|---|
| SAVOR TIMI | Saxagliptin | Add saxagliptin versus placebo to standard of care | CV death, AMI, or stroke | 18,206 | 2.1 | ≥40 | ≥6.5 | CVD or high cardiovascular risk |
| EXAMINE | Alogliptin | Add alogliptin versus placebo to standard of care | CV death, AMI, or stroke | 5380 | 1.5 | ≥18 | 6.5–11 | Acute coronary syndrome within previous 15–90 days |
| TECOS | Sitagliptin | Sitagliptin versus placebo | CV death, AMI, unstable angina, or stroke | 14,724 | 3 | ≥50 | 6.5–11 | Preexisting CVD |
| ELIXA | Lixisenatide | Lixisenatide versus placebo | CV death, AMI, unstable angina, or stroke | 6076 | 2.1 | ≥30 | ≥7 | Acute coronary syndrome within previous 180 days |
| EMPA-REG outcome |
Empagliflozin | Empagliflozin 10 mg versus 25 mg versus placebo | CV death, AMI, or stroke | 7000 | 3.1 | ≥18 | 7–10 | Preexisting CVD |
| LEADER | Liraglutide | Liraglutide versus placebo | CV death, AMI, or stroke | 9340 | 3.8 | ≥50 | ≥7 | ≥50 yrs with preexisting disease: CVD/cerebrovascular/renal disease/HF or ≥60 yrs with high CV risk |
| SUSTAIN-6 | Semaglutide | Semaglutide 0.5 mg versus 1 mg versus placebo | CV death, AMI, or stroke | 3299 | 1.99 | ≥50 | ≥7 | ≥50 yrs with preexisting CVD or ≥60 yrs with high cardiovascular risk |
| EXSCEL | Exenatide | Exenatide 2 mg weekly versus placebo | CV death, AMI, or stroke | 14,752 | 3.2 | ≥50 | 6.5–10 | 70% preexisting CVD |
| CANVAS | Canagliflozin | CANVAS Canagliflozin 300 mg versus canagliflozin 100 mg versus placebo |
CV death, AMI, or stroke | 10,142 (4330 CANVAS, 5812 CANVAS-R) |
5.69 (CANVAS) 2 (CANVAS-R) |
≥50 | 7–10.5 | ≥30 yrs with atherosclerotic disease or ≥50 yrs with 3 or more CV risk factors |
| CANVAS-R Canagliflozin 100 mg with optional increase to 300 mg versus placebo |